|
Metronomic oral maintenance chemotherapy in patients with localized high-risk rhabdomyosarcoma (RMS) and RMS-like tumors: A report from a randomized, multicenter, phase III trial CWS-2007HR. |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Bayer; Roche; SOBI |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Apeiron Biologics; Boehringer Ingelheim; EUSA Pharma |
Consulting or Advisory Role - Apeiron Biologics; Boehringer Ingelheim; EUSA Pharma (Inst) |
Research Funding - Apeiron Biologics (Inst); EUSA Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - Apeiron Biologics (Inst); EUSA Pharma (Inst) |
Expert Testimony - Apeiron Biologics; EUSA Pharma |
Travel, Accommodations, Expenses - Apeiron Biologics; EUSA Pharma |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - SERVIER |
Research Funding - SERVIER |
| |
|
Consulting or Advisory Role - Amgen Astellas BioPharma; Teva |
Speakers' Bureau - Amgen Astellas BioPharma |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Irene Teichert von Luettichau |
Consulting or Advisory Role - Bayer |
| |
|
Consulting or Advisory Role - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |